Glucoryl.

SKU's of Glucoryl Group

• Glucoryl

• Glucoryl -M1 & M2

• Glucoryl -MV .2/.3

• Glucoryl -MP

• Glucoryl -M1 & M2 forte

Target specialty for Glucoryl Group Promotion

• Diabeto/ Cardio/ GP

• Diabeto/ cardio/ CP

• Diabeto/ Nephro/ GP

• Diabeto/ Neuro/ GP

• Diabeto/ Cardio/ Nephro

MOA of Glucoryl is

• Increase Insulin Secretion

• Induces PPAR- Gamma

• Increases Glut- 4 translocation

• improving peripheral utilization of glucose

Match the following Pharmacokinetics of Glucoryl.

• Excretion

• 2-3 Hrs

• Half Life

• >99%

• Tmax

• kidney -60%

  liver- 40%

• bioavailability

• 6-9 Hrs

• PPB

• 100%

Expancreatic effect Of Glucoryl is

• Improve insulin sensitivity & Action

• Reduces Insulin resistance,

• decreases HGO

  Increases Peripheral utilization of Glucose

• lowest BI/ BG ratio

• Induces PPAR-Gamma

  increases 4 fold in GLUT-4 Translocation

Maximum dosage of Glucoryl per day is

• 8 mg/day

• 4 mg/day

• 2 mg/day

• 6 mg/day

Match the following Details of Carolina Trial

• patients on lingliptin

• 3023

• Result

• 6.3 Yrs

• HbA1C

• 3010

• duration

• 3p mace

  11.8% Linagliptin

  12% glimepiride

• Patients on Glimepiride

• 6.5-8.5%

Match the following USP of Glucoryl

• No hypoglycemia, weight Gain

• 2-3 times faster association with sulphonyl urea

• faster onset of action

• 24 Hr blood glucose level Control

• OD dosing

• 8-9m times faster dissociation from receptor

• less cardiovascular side effect

• No effect on Cardiac kATP

Benefits of Glucoryl M are

• Meal independent, OD dosing

• Effective glycemic control & avoiding Insulin for 7.9 Yrs

• No hyperinsulinemia, no hypoglycemia

• preserves Beta cells, shows weight reducing effect.

ADA, EASD 2019, recommends Glucoryl M as Safe & effective in diabetic Patients with

• Established ASCVD

• Heart failure

• Chronic kidney disease

• Economy